

Program 52. årsmøde

Hindsgavl Slot, 8. – 9. marts 2024

Fredag den 8. marts

12.00-13.00 Frokost

13.00-13.10 Velkomst ved DHS formand Jakob Madsen

Fremtidens beslutningsværktøjer

Chairman: Tarec El-Galaly

13.10 – 13.50 Erfaringer fra nationale PRO projekter
Helle Pappot, professor
Afdeling for Kræftbehandling, RH

13.50 – 14.30 AI i sundhedsvæsenet – udvikling, implementering og udbredelse
Peter Børker Nielsen, chefkonsulent
Centre for Clinical Artificial Intelligence (CAI-X), OUH

14.30 – 15.15 Kaffe og udstilling

15.15 – 15.50 AI modeller i CLL
Rudi Agius
Afdeling for Blodsygdomme, RH

15.50 – 16.30 Fælles Beslutningstagning
Karina Dahl Steffensen, professor og cheflæge
Center for Fælles Beslutningstagning, Sygehus Lillebælt

16.30-16.45 Årets case

Generalforsamling

17.00 - 18.00 Generalforsamling (kun for ordinære medlemmer af DHS)

Kåring af årets hæmatolog

Afstemning foregår via Zoom. Download venligst app til din telefon på forhånd.

Middag

18.30 - 19.00 Velkomstdrink og udstilling

19.00 - Middag

Lørdag den 9. marts

Abstract session 1

Chairpersoner: Jens Helby, RH og Peter Asdahl, AUH

9.00-9.10	Thomas Lacoppidan, Christian Brieghel, Casper Møller Frederiksen and Carsten Utoft Niemann.	Infection burden upon treatment of lymphoid-lineage cancers
9.10-9.20	Jelena Jelacic, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen	The impact of NCCN-IPI versus IPI as selection criteria in trial eligible Diffuse large B-cell lymphoma patients: A Real-World data analysis
9.20-9.30	Jojo Biel-Nielsen Dietz, Ólafur Birgir Davidsson, Ragnar Pétur Kristjánsson, Sigrun Thorsteinsdottir, Agoston Gyula Szabo, Carsten Utoft Niemann, Henrik Hjalgrim, Christian Brieghel	Prior opioid use is predictive of MM survival
9.30-9.40	Dicte Træden, Morten Tulstrup, Morten Munk Johansen, Andreas Due Ørskov, Claus Marcher, Klas Raaschou-Jensen, Anne Stidsholt Roug, Marianne Tang Severinsen, Bo Porse, Kim Theilgaard-Mönch, Kåre Nielsen, Maymana Salih, Jakob Jespersen, Jack B. Cowland, Lene Sjö, Mette Klarskov Andersen, Kirsten Grønbæk, Jakob Werner Hansen	Langtidsopfølgning af patienter med klonal cytopeni af ukendt signifikans (CCUS)
9.40-9.50	Kort pause/opsamling	
9.50-10.00	Anders Blach Naamansen, Dennis Lund Hansen, Jesper Petersen, Andreas Glenthøj, Henrik Frederiksen	The risk of gallstones in patients with congenital red blood cell disorders: A nationwide cohort study
10.00-10.10	Anne Rudbeck Juhl, Andreas Glenthøj, Børge Grønne Nordestgaard, Jesper Petersen, Morten Dahl, Christina Ellervik, Stig Egil Bojesen, Jens Helby	Absolute and Relative Risk of Hematologic Disease and Cause-specific Death in Individuals with Incidentally Discovered Thrombocytopenia: a Prospective Study of Two Independent General Population Cohorts Including 486,735 Individuals from the United Kingdom and Denmark
10.10-10.20	Dana A. Lawrie, Dennis L. Hansen, Thomas D. Leineweber, Sarah B.I.S. Carlsen, Louise H. Hannig, Per T. Pedersen, Helene B. Kristensen, Mads O.B. Lorenzen, Jesper Stentoft, Peter B. van Kooten Niekerk, Maren P. Jørgensen, Marianne T. Severinsen, Mikkel H. Dorff, Robert S. Pedersen, Andreas Glenthøj, Henrik Frederiksen	Thrombotic thrombocytopenic purpura and Evans syndrome: validity of diagnoses nationwide and a brief outline of 20 years of routine hospital care
10.20-10.30	Mikkel Werling, Christian Brieghel, Casper Møller Frederiksen, Mehdi Parviz, Caspar da Cunha-Bang, Tereza Faitova, Rebecca Svanberg Teglgaard, Noomi Vainer, Thomas Lacoppidan, Emelie Rotbain, Rudi Agius, Carsten Utoft Niemann	The Danish Lymphoid Cancer Research (DALY-CARE) data resource

10.30-11.00

Formiddagspause

Abstract session 2

Chairpersoner: Marie Bill, AUH og Cecilie Rank, RH

11.00-11.10	Emil Ramsø Kyvsgaard, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Lene Sjø, Linea Melchior, Kirsten Grønbæk, Martin Hutchings, Simon Husby	Identifikation af patienter som responderer på CD20xCD3 bispecifikke antistoffer mod lymfom
11.10-11.20	Michael T. Gundesen, Thomas Lund, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold	Treatment of patients with multiple myeloma with zoledronic acid for four years instead of two years decreases risk of progressive bone disease
11.20-11.30	Stine Ulrik Mikkelsen, Anders Pommer Vallentin, Amalie Bach Nielsen, Morten Rytter Tulstrup, Jakob Werner Hansen, Bo Kok Mortensen, Marianne Tang Severinsen, Casey O'Connell, Jakob Schmidt Jespersen, Mette Klarskov Andersen, Jens Lykkesfeldt, Peter A. Jones, Kirsten Grønbæk	Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low-risk myeloid malignancies: Preliminary results from EVI-2, a randomized, placebo- controlled pilot study
11.30-11.40	Ruth Salim, Christian Winther Eskelund, Mats Jerkeman, Arne Kolstad, Riikka Rätty, Martin Hutchings, Christian Geisler, Carsten Utoft Niemann, Lone Bredo Pedersen, Trine Trab, Jonas Skjold Raaschou-Pedersen, Juan Luis Garcia Rodriguez, Lasse Sommer Kristensen, Mette Dahl, Kirsten Grønbæk	Exploring the prognostic performance of circSCORE in patients with relapsed/refractory mantle cell lymphoma
11.40-11.50	Kort pause/opsamling	
11.50-12.00	Nanna E. Andersen, Ditte B. Iversen, Christina Mortensen, Mark Burton, Christoffer S. Jensen, Jonna S. Madsen, Niels Abildgaard, Mette Kathrine Nygaard, Astrid Terkelsen, Mads Thomassen, Mette Marie H. Christensen, Thomas Lund, Ida B. Kristensen, Per Damkier, Tore B. Stage	Neurofilament light chain as biomarker for bortezomib-induced peripheral neuropathy and molecular mechanisms of bortezomib-induced in vitro neurotoxicity
12.00-12.10	Nikolaj Juul Nitschke, Marwa Almosaileakh, Casper Carstens Lund, Morten Frodin, Mette Klarskov Andersen, Kirsten Grønbæk	Functional characterization of DDX41 variants
12.10-12.20	Thomas Lund, Jannie Kirkegaard, Tine Rosenberg, Michael Tveden Gundesen, Karin Dieperink	Home treatment and dosing of follow-up anti-neoplastic treatment based on digital patient reported outcomes data in patients with multiple myeloma
12.20-12.30	Johanne Skovgaard Schovsbo, Henrik Sengeløv, Kristina Holmegaard Nørskov, Lars Kjeldsen, Lone Smidstrup Friis	Outpatient management of patients receiving treatment with Fludarabine and Treosulfan conditioning prior to allogeneic hematopoietic stem cell transplantation

12.30-13.00

Afslutning og sandwich